Mirror PR to Forgejo / mirror (pull_request) Waiting to run

Details

vida: extract claims from 2026-04-24-glp1-oud-rct-protocol-nct06548490-penn-state

- Source: inbox/queue/2026-04-24-glp1-oud-rct-protocol-nct06548490-penn-state.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

2026-04-24 04:15:38 +00:00

3.2 KiB

Raw Blame History

NCT06548490: Semaglutide for OUD Phase 2 RCT

Type: Clinical Trial Protocol Status: Active (ongoing, no results) Phase: 2 Design: Randomized, double-blind, placebo-controlled Registration: NCT06548490 Principal Investigator: Patricia S. Grigson, Penn State Funding: NIH Publication: Addiction Science & Clinical Practice, 2025

Trial Design

Population:

200 participants with treatment-refractory opioid use disorder
Already receiving standard MOUD (buprenorphine or methadone)
Outpatient setting
Three sites

Intervention:

Semaglutide vs. placebo
12-week treatment period
Added to existing MOUD background therapy

Primary Endpoint:

Opioid abstinence (confirmed by urine drug screens + self-report)

Scientific Rationale

Preclinical Evidence:

Rodent models show GLP-1 receptor agonists reduce opioid self-administration
Mechanism: GLP-1 receptors in ventral tegmental area modulate dopamine reward circuits

Clinical Evidence (pre-trial):

Residential OUD population studies show decreased craving measures
Qeadan 2025 real-world data: 40% lower opioid overdose rate in GLP-1 RA users
No completed controlled trials in outpatient OUD as of protocol publication

Safety Considerations

Documented Concerns:

Pancreatic cysts and cancer risk
Hypoglycemia
Muscle cramps
Cognitive slowing
Drug interactions with buprenorphine/methadone

Population Risk:

Treatment-refractory patients represent high-difficulty population
Higher baseline risk for adverse outcomes

Significance

Why This Trial Matters:

Only active well-powered Phase 2 RCT for GLP-1 in OUD
Tests whether real-world observational signal (Qeadan 2025) holds under controlled conditions
Specifically targets treatment-refractory population (not achieving abstinence with standard MOUD)
Will determine if GLP-1 reward circuit mechanism extends beyond food/alcohol to opioids

Expected Timeline:

Results anticipated 2026-2027
Positive result would elevate GLP-1 OUD mechanism claim from "experimental" to "likely" confidence
Null result would suggest mechanism specificity to food/alcohol reward circuits

Timeline

2025 — Protocol published in Addiction Science & Clinical Practice
2025-2026 — Trial enrollment and treatment ongoing
2026-2027 — Results expected (monitoring required)

Research Context

Patricia Grigson is a leading addiction neuroscience researcher at Penn State College of Medicine. This NIH-funded trial represents the first rigorous controlled test of GLP-1 receptor agonists for opioid use disorder in an outpatient population already receiving medication-assisted treatment.

Monitoring Notes

Status: Protocol-only publication. No results available as of April 2026.

Action Required: Monitor for results publication Q3/Q4 2026 or early 2027. Results will directly inform whether the GLP-1 reward circuit mechanism claim can extend to opioids with "likely" confidence.

KB Impact: When results publish, this becomes a primary source for evaluating the OUD extension of the existing claim "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"

3.2 KiB Raw Blame History